Pertwee Roger G
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, Scotland, UK.
Mol Neurobiol. 2007 Aug;36(1):45-59. doi: 10.1007/s12035-007-0005-2. Epub 2007 Jun 26.
This review discusses clinical and preclinical evidence that supports the use of cannabinoid receptor agonists for the management of multiple sclerosis. In addition, it considers preclinical findings that suggest that as well as ameliorating signs and symptoms of multiple sclerosis, cannabinoid CB(1) and/or CB(2) receptor activation may suppress some of the pathological changes that give rise to these signs and symptoms. Evidence that the endocannabinoid system plays a protective role in multiple sclerosis is also discussed as are potential pharmacological strategies for enhancing such protection in the clinic.
本综述讨论了支持使用大麻素受体激动剂治疗多发性硬化症的临床和临床前证据。此外，还考虑了临床前研究结果，这些结果表明，除了改善多发性硬化症的体征和症状外，大麻素CB(1)和/或CB(2)受体激活可能会抑制一些导致这些体征和症状的病理变化。还讨论了内源性大麻素系统在多发性硬化症中起保护作用的证据，以及在临床上增强这种保护作用的潜在药理学策略。
